Technical Analysis for CERS - Cerus Corporation

Grade Last Price % Change Price Change
grade D 6.22 1.63% 0.10
CERS closed up 1.63 percent on Monday, March 18, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical CERS trend table...

Date Alert Name Type % Chg
Mar 18 Lower Bollinger Band Walk Weakness 0.00%
Mar 18 Lower Bollinger Band Touch Weakness 0.00%
Mar 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.63%
Mar 15 BB Squeeze Ended Range Expansion 1.63%
Mar 15 Below Lower BB Weakness 1.63%
Mar 15 Down 3 Days in a Row Weakness 1.63%
Mar 15 Lower Bollinger Band Touch Weakness 1.63%
Mar 14 New Downtrend Bearish 0.81%
Mar 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.81%
Mar 14 Bollinger Band Squeeze Range Contraction 0.81%

Older signals for CERS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company's INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. Its INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; and INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion. The company is also developing INTERCEPT Blood System for red blood cells, which is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets its platelet and plasma systems through its direct sales force and distributors primarily in Europe, the Commonwealth of Independent States, and the Middle East. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Anatomy Blood Transfusion Medicine Commonwealth Day Hematology Blood Products Coagulation System Blood Transfusion Commonwealth Of Independent States Platelet Red Blood Cell
Is CERS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.05
52 Week Low 4.705
Average Volume 734,944
200-Day Moving Average 6.4354
50-Day Moving Average 6.073
20-Day Moving Average 6.4635
10-Day Moving Average 6.359
Average True Range 0.2691
ADX 28.88
+DI 9.2741
-DI 25.8076
Chandelier Exit (Long, 3 ATRs ) 6.0727
Chandelier Exit (Short, 3 ATRs ) 6.5273
Upper Bollinger Band 6.8151
Lower Bollinger Band 6.1119
Percent B (%b) 0.15
BandWidth 10.879554
MACD Line 0.036
MACD Signal Line 0.1106
MACD Histogram -0.0746
Fundamentals Value
Market Cap 678.82 Million
Num Shares 109 Million
EPS -0.61
Price-to-Earnings (P/E) Ratio -10.20
Price-to-Sales 8.39
Price-to-Book 7.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.54
Resistance 3 (R3) 6.53 6.43 6.48
Resistance 2 (R2) 6.43 6.35 6.43 6.47
Resistance 1 (R1) 6.32 6.30 6.38 6.33 6.45
Pivot Point 6.22 6.22 6.24 6.22 6.22
Support 1 (S1) 6.11 6.14 6.17 6.11 5.99
Support 2 (S2) 6.01 6.09 6.01 5.97
Support 3 (S3) 5.90 6.01 5.96
Support 4 (S4) 5.90